CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gordon James who wrote (410)	11/29/1999 9:12:00 PM
From: RWReeves	Read Replies (2) of 666

A time honored function of marketing is to take problems and make them into features. I can't help thinking Bex's dosimetry is like that. The whole dosimetry shuffle will increase the complexity and cost of the treatment and make it vulnerable to a cheaper, easier therapy. I still have trouble with the idea of a gamma emitter coupled to the specificity of an antibody for delivery- I think somebody succinctly posted a while back that just the WBI from the hot Iodine without the Ab would likely give you equivalent results. I have to wonder if the market isn't really looking for a dose calculated on the normal parameters instead of titration. Of course, this is long run, immediately, efficacy will do the trick. Efficiency comes later. Sorry this sounds like Short Stuff, I've been long on them several times but feel the world is catching up to them quickly. RWR

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next